{"eventGroups":[{"deathsNumAffected":4,"deathsNumAtRisk":12,"description":"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.\n\nIMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors).\n\nfludarabine phosphate: Given IV melphalan: Given IV total-body irradiation: Undergo TBI mycophenolate mofetil: Given PO cyclosporine: Given PO nonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nperipheral blood stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT laboratory biomarker analysis: Correlative s","id":"EG000","otherNumAffected":9,"otherNumAtRisk":12,"seriousNumAffected":4,"seriousNumAtRisk":12,"title":"Related Donor"},{"deathsNumAffected":1,"deathsNumAtRisk":4,"description":"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.\n\nIMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors).\n\nfludarabine phosphate: Given IV melphalan: Given IV total-body irradiation: Undergo TBI mycophenolate mofetil: Given PO cyclosporine: Given PO nonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nperipheral blood stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT laboratory biomarker analysis: Correlative s","id":"EG001","otherNumAffected":2,"otherNumAtRisk":4,"seriousNumAffected":1,"seriousNumAtRisk":4,"title":"Unrelated Donor"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":12,"numEvents":3},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Acute kidney injury"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Adult respiratory distress syndrome"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Alanine aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Anorexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Blood bilirubin increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Bone marrow hypocellular"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Creatinine increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Fever"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Generalized muscle weaknes"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Heart failure"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Hypotension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Hypoxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Lung infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Mucositis oral"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Pneumonitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Respiratory failure"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Supraventricular tachycardia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Syncope"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Thrombotic thrombocytopenic purpura"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Adult respiratory distress syndrome"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Blood bilirubin increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":4,"numEvents":0}],"term":"Multi-organ failure"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":4,"numEvents":1}],"term":"Respiratory failure"}],"timeFrame":"AEs: Conditioning through Day 100; SAEs: Conditioning through Day 200"}